// App-Quantinova.ai

e12515 : Tailored neoadjuvant epirubicin and cyclophosphamide (EC) and nanoparticle albumin-bound paclitaxel (nab-P) in breast cancer.

Researchers

Presenter

  • Mustafa Khasraw

Principal Investigators

  • Violet Rudo Mukaro

  • Linda West

  • Karen White

  • Elisabeth Rippy

  • Conrad Brandt

  • Robert Tobler

  • Caitlin Clare Murphy

  • Ian M. Collins

  • Sally E. Baron-Hay

  • David M. Ashley

  • Sujata Patil

Medical Centers

  • NHMRC CTC, The University of Sydney, Camperdown NSW, Australia

  • Barwon Health, Geelong, LA, Australia

  • Lake Imaging Geelong, Geelong, Australia

  • North Shore Private Hospital, St Leonards, Australia

  • The Geelong Hospital, Geelong, Australia

  • The Geelong Hospital, Fitlroy, VIC, Australia

  • Wentworth Street Consulting Suites, Warrnambool, Australia

  • Medical Oncology Department, Royal North Shore Hospital, St Leonards, Australia

  • Andrew Love Cancer Centre, Geelong, Australia

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • United States

  • Australia

Companies

  • Wentworth Street Con

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Triple-negative breast cancer

Biomarkers

  • N/A

Drug/Treatment

  • Protein-bound paclitaxel

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Trastuzumab

  • Epirubicin

  • Paclitaxel

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • NCT01830244

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved